Most patients with mild or moderate hemophilia A circulate a point-mutated, partially disabled FVIII protein and require only rare infusions of therapeutic FVIII, indicative of they are less likely to develop an ADA response (38, 39). The gene discussed is ADA; the disease is hemophilia A.